Articles Referencing AZN
Good News for Roche's Tarceva - Analyst Blog
5/16/2013, 6:27 pm from Zacks.com in Investing, Business, Stocks
Roche ( RHHBY ) recently
announced that the US Food and Drug Administration (FDA) has
approved Tarceva (erlotinib) tablets for the first line treatment
of patients suffering from metastatic... Read >>
Wider-than-Expected Loss at Optimer - Analyst Blog
5/10/2013, 12:23 pm from Zacks.com in Investing, Business, Stocks
Optimer Pharmaceuticals Inc. 's ( OPTR ) first quarter
2013 net loss (excluding special items) of 65 cents per share was
wider than the Zacks Consensus Estimate of a loss of 42 cents... Read >>
Narrower-Than-Expected Loss at Rigel Pharma - Analyst Blog
5/9/2013, 10:00 am from Zacks.com in Investing, Business, Stocks
Rigel Pharmaceuticals ' ( RIGL ) first-quarter
2013 loss of 29 cents per share was narrower than both the Zacks
Consensus Estimate as well as the year-ago quarter loss of 32
cents. The... Read >>
Will DENTSPLY Beat Earnings in 1Q? - Analyst Blog
5/8/2013, 3:21 pm from Zacks.com in Investing, Business, Earnings, Stocks
DENTSPLY International 's ( XRAY ) is set to
report its first-quarter 2013 results before the opening bell on
Thursday, May 9. Let us see how things are shaping up prior to... Read >>
Isis Initiates ISIS-STAT3 Study - Analyst Blog
5/7/2013, 6:23 pm from Zacks.com in Investing, Business, Stocks
Isis Pharmaceuticals, Inc. ( ISIS ) recently
announced the initiation of a phase Ib/IIa study on an oncology
candidate, ISIS-STAT3 (also known as AZD9150), for advanced
metastatic... Read >>
Wider-than-Expected Loss at Dynavax - Analyst Blog
5/7/2013, 11:26 am from Zacks.com in Investing, Business, Stocks
Dynavax Technologies Corporation ( DVAX ) suffered a loss
of 11 cents per share in the first quarter of 2013, wider than the
Zacks Consensus Estimate of a loss of 10 cents per share but... Read >>
This May Be The Best Pharmaceutical Stock for Income Investors
5/3/2013, 9:30 am from StreetAuthority in Investing, Investing Ideas, Stocks
As an income investor, I feel like I've hit the trifecta when I
find a low-risk stock that also has consistent dividend growth and
a fantastic yield. The high-quality dividend stocks I look... Read >>
Amarin's Performance Issues: Here To Stay?
4/29/2013, 1:30 pm from SeekingAlpha in Investing, Stocks
ByDallas Salazar: Amarin Corporation ( AMRN ) is one of the
most controversial and debated stocks in recent memory. Plenty of
information exists that helps validate both the bull and bear... Read >>
AstraZeneca Earnings Tumble Y/Y - Analyst Blog
4/26/2013, 1:03 pm from Zacks.com in Investing, Business, Earnings, Stocks
AstraZeneca 's ( AZN ) first-quarter
2013 core earnings of $1.41 per American Depositary Share (ADS)
beat the Zacks Consensus Estimate of $1.34. Earnings were down 21%
(at constant... Read >>
Loss Widens at Ironwood - Analyst Blog
4/24/2013, 4:10 pm from Zacks.com in Investing, Business, Stocks
Ironwood Pharmaceuticals, Inc. 's ( IRWD ) first-quarter
2013 loss of 87 cents per share compared unfavorably with the
year-ago loss of 34 cents per share. Results were primarily hurt... Read >>
AZN/BIND Therapeutics Ink Deal - Analyst Blog
4/23/2013, 7:11 pm from Zacks.com in Investing, Business, Stocks
AstraZeneca ( AZN ) recently
announced that it has entered into an agreement with BIND
Therapeutics for the development and commercialization of Accurin
(a cancer nanomedicine).
As per... Read >>
Inovio Reports Promising Data - Analyst Blog
4/19/2013, 4:00 pm from Zacks.com in Investing, Business, Stocks
Inovio Pharmaceuticals, Inc. ( INO ) recently
announced encouraging data from a phase I study on its influenza
vaccine candidate, SynCon. SynCon is being developed as a universal
H1N1... Read >>
AZN Inks Biomarker Discovery Deal - Analyst Blog
4/18/2013, 7:10 pm from Zacks.com in Investing, Business, Stocks
AstraZeneca ( AZN ) recently
announced that it has entered into an agreement with UK-based
company, Oxford Cancer Biomarkers Ltd. As per the terms of the
agreement, Oxford Cancer Biomarkers... Read >>
Santarus to Make Cash Milestone Payment - Analyst Blog
4/18/2013, 5:12 pm from Zacks.com in Investing, Business, Stocks
Santarus Inc. ( SNTS ) was recently
notified that Cosmo Technologies Limited, a subsidiary of Cosmo
Pharmaceuticals S.p.A., agreed to receive a commercial milestone
payment of $7.0 million... Read >>
Under The Hood: An ETF For International Income
4/18/2013, 3:33 pm from Benzinga in Investing, ETFs, International, Investing Ideas
This week has been kind to income investors looking for new ETFs to consider
as Northern Trust's (NASDAQ: NTRS ) FlexShares unit
has rolled out three new global dividend funds
. The... Read >>